Last updated on April 2019

Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF


Brief description of study

The primary hypothesis in this trial is that the treatment with vericiguat 10 mg or 15 mg in patients with HFpEF improves the KCCQ PLS (Kansas City Cardiomyopathy Questionnaire Physical limitation score) compared to placebo after 24 weeks of treatment.

Clinical Study Identifier: NCT03547583

Find a site near you

Start Over

WestSide Medical

Beverly Hills, CA United States
  Connect »

Penrose-St. Francis Health Services

Colorado Springs, CO United States
  Connect »

Cardiology Research Associates

Daytona Beach, FL United States
  Connect »

East Coast Institute for Research, LLC

Saint Augustine, FL United States
  Connect »

Cardiology Partners

Wellington, FL United States
  Connect »

Reid Health

Richmond, IN United States
  Connect »

Research Integrity, LLC

Owensboro, KY United States
  Connect »

Grace Research, LLC

Bossier City, LA United States
  Connect »

Heart Clinic of Hammond

Hammond, LA United States
  Connect »

Anne Arundel Health System

Annapolis, MD United States
  Connect »

Henry Ford Health System

Detroit, MI United States
  Connect »

St. Louis Heart & Vascular, PC

Saint Louis, MO United States
  Connect »

Bryan Heart

Lincoln, NE United States
  Connect »

Hudson Valley Urology Center

Poughkeepsie, NY United States
  Connect »

Wake Forest Baptist Health

Winston-Salem, NC United States
  Connect »

Capital Area Research, LLC

Camp Hill, PA United States
  Connect »

Allegheny General Hospital

Pittsburgh, PA United States
  Connect »

Kent Hospital

Warwick, RI United States
  Connect »

Carolina Heart Specialists

Lancaster, SC United States
  Connect »

Stern Cardiovascular Center

Germantown, TN United States
  Connect »

Grace Research, LLC

Huntsville, TX United States
  Connect »

Inova Fairfax Hospital

Falls Church, VA United States
  Connect »

ZNA Middelheim

Antwerpen, Belgium
  Connect »

CU Saint-Luc/UZ St-Luc

Bruxelles - Brussel, Belgium
  Connect »

UZ Antwerpen

Edegem, Belgium
  Connect »

AZ Delta

Roeselare, Belgium
  Connect »

V MHAT

Sofia, Bulgaria
  Connect »

CardioVasc HR, Inc.

Saint-Jean-sur-Richelieu, QC Canada
  Connect »

Tokyo Heart Center

Shinagawa-ku, Japan
  Connect »

City hospital #15

St. Petersburg, Russian Federation
  Connect »

Queenswood CTC

Queenswood, South Africa
  Connect »

TREAD Research cc

Cape Town, South Africa
  Connect »

Tiervlei Trial Centre

Cape Town, South Africa
  Connect »

Groote Schuur Hospital

Cape Town, South Africa
  Connect »

Vergelegen Medi-Clinic

Somerset West, South Africa
  Connect »

Advocate Condell Medical Center

Libertyville, IL United States
  Connect »

Hutchinson Clinic

Hutchinson, KS United States
  Connect »

Phillips Medical Services

Jackson, MS United States
  Connect »

Life Spring Research

Coral Gables, FL United States
  Connect »

M. Reddy Cardiology

Baytown, TX United States
  Connect »

Corporation Lane Research Center

Virginia Beach, VA United States
  Connect »

Clinical Advancement Center, PLLC

San Antonio, TX United States
  Connect »

Salem VA Medical Center

Salem, VA United States
  Connect »

St.Petersburg City hospital 38 n.a. N.A. Semashko

Pushkin, Saint Petersburg, Russian Federation
  Connect »

Riser Medical Associates

Picayune, MS United States
  Connect »

Cl nica DIM

Ramos Mejía, Argentina
  Connect »

CICLAM

Medellín, Colombia
  Connect »

Cl nica Medell n

Medellín, Colombia
  Connect »

Kliniken Maria Hilf GmbH

Mönchengladbach, Germany
  Connect »

City Pokrovskaya Hospital

St. Petersburg, Russian Federation
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.